Estados Unidos · Plataformas y datos · MarketBeat

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

Publicado por MarketBeat · Estados Unidos hace 1 h

LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride,…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

También te puede interesar

All It Takes Is $5,000 Invested in Enterprise Products Partners (EPD) to Generate $300 in Annual Passive Income

Sensata expects Q4 revenue of $942M-$972M and adjusted EPS of $0.95-$0.99 as China auto outlook softens

Earnings call transcript: ASMPT posts record bookings in Q3 2026 on AI demand

Retail traders buy the dip on chip stocks — but Robinhood gets burned by the crypto market

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Popular crypto stock surges as Q3 earnings top estimates

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

Compartir

También te puede interesar

All It Takes Is $5,000 Invested in Enterprise Products Partners (EPD) to Generate $300 in Annual Passive Income

Sensata expects Q4 revenue of $942M-$972M and adjusted EPS of $0.95-$0.99 as China auto outlook softens

Earnings call transcript: ASMPT posts record bookings in Q3 2026 on AI demand

Retail traders buy the dip on chip stocks — but Robinhood gets burned by the crypto market

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Popular crypto stock surges as Q3 earnings top estimates